Mutz Christopher's Form 4 filing
Ani Pharmaceuticals IncANIP · filed Feb 17, 2026
- Accession no.
- 0001846487-26-000004
- Filed
- Feb 17, 2026
- Trade date
- Feb 12-14, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $538.3K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mutz ChristopherCIK 0001846487 | Officer (HEAD OF RARE DISEASE) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | Common Stock | FTax withholdingDisposed | −3,173 | $76.70 | −$243,369.1 | 99,598 | Direct | |
| Feb 12, 2026 | Common Stock | SSaleDisposed | −7,032 | $76.55F3 | −$538,299.6 | 92,566 | Direct | |
| Feb 14, 2026 | Common Stock | FTax withholdingDisposed | −2,403 | $77.36 | −$185,896.08 | 90,163 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The shares were sold in multiple trades at prices ranging from $75.43 to $76.92. The price reported above reflects the weighted average sales price.
Referenced by the price of 1 transaction in Table I.